Skip to main content
. Author manuscript; available in PMC: 2013 Oct 1.
Published in final edited form as: J Bone Miner Res. 2012 Oct;27(10):2130–2143. doi: 10.1002/jbmr.1669

Figure 3. Alendronate (ALN) and a high dose of zoledronic acid (ZOL) prevent maxillary alveolar bone loss (ABL) observed with the high sucrose and casein diet after 18 wks of treatment.

Figure 3

ALN (15μg/kg) was given SC biweekly. ZOL was administered either at a low dose (LD; 8 μg/kg) or high dose (HD; 80 μg/kg) IV once monthly. Maxillary horizontal ABL at the palatal surface of males (A), buccal surface of males (B), palatal surface of females (C), and buccal surface of females (D). An asterisk denotes a significant difference from its respective time-matched vehicle-treated group. ANOVA. (P < 0.05).